Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Psychiatric Quarterly
Published in: Psychiatric Quarterly 2/2008

01-06-2008 | Original Paper

Both Atomoxetine and Stimulants Improve Quality of Life in an ADHD Population Treated in a Community Clinic

Author: Leo Bastiaens

Published in: Psychiatric Quarterly | Issue 2/2008

Login to get access

Abstract

Objective

To evaluate change in quality of life in a community clinic ADHD population treated with atomoxetine or stimulants. No direct comparisons between atomoxetine and stimulants to improve quality of life in ADHD are available.

Methods

A prospective, nonrandomized comparison between ADHD patients treated with atomoxetine or stimulants in one clinic. Structured diagnostic assessment tools and a specific quality of life measure were used.

Results

84 patients (atomoxetine n = 39/stimulants n = 45), between the ages of 5 and 18, were treated for approximately 8 months. At end point, there were no significant differences in improvements of quality of life between the two groups. Age, participation in psychotherapy, and parental disability were not correlated with quality of life changes. Patients with lower baseline scores improved most.

Conclusions

Both atomoxetine and stimulants led to a modest increase in quality of life in this community clinic ADHD population.
Literature
1.
Klassen AF, Miller A, Fine S: Health related quality of life in children and adolescents who have a diagnosis of ADHD. Pediatrics 114:e541–e547, 2004PubMedCrossRef
2.
Escobar R, Soutullo CA, Hervas A: Worse quality of life for children with newly diagnosed attention deficit hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 116:e364–e369, 2005PubMedCrossRef
3.
Perwien AR, Faries DE, Kratochvil CJ, et al.: Improvement in health-related quality-of-life in children with ADHD: an analysis of placebo-controlled studies of atomoxetine. Journal of Developmental and Behavioral Pediatrics 25:264–271, 2004PubMedCrossRef
4.
Lopez FA, Chandler MC, Biederman J, et al.: Long-term Adderall XR treatment improves quality of life in ADHD children. Abstract presented at the 156th annual meeting of the American Psychiatric Association, 2003
5.
Bastiaens L, Dello Stritto C: Quality of life of children and adolescents during psychiatric treatment in a community mental health setting. Psychiatry 2:32–35, 2005
6.
Bastiaens L: Effectiveness and tolerability of atomoxetine in a real-world ADHD population. Psychiatry 4(12):44–48, 2007
7.
Sheehan DV, Lecrubier Y, Harnett Sheehan K, et al.: The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. European Psychiatry 12:232–241, 1997CrossRef
8.
Gadow KD, Sprafkin J: Adolescent Symptom Inventory-4. Stony Brook, NY, Checkmate Plus LTD, 1997
9.
Bastiaens L, Dello Stritto C: Validity and reliability of the Health and Life Functioning Scale. Abstract presented at the 51st annual meeting of the American Academy of Child and Adolescent Psychiatry, 2004
10.
Geller D, Donnelly C, Lopez F: Atomoxetine treatment for pediatric patients with attention deficit hyperactivity disorder and comorbid anxiety. Journal of the American Academy of Child and Adolescent Psychiatry 46(9):1119–1127, 2007PubMedCrossRef
11.
Prasad S, Harpin V, Poole L: A multicentre randomised open label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention deficit hyperactivity disorder. Current Medical Research and Opinion 23(2):379–394, 2007PubMedCrossRef
12.
Bastiaens L: Pediatric psychopharmacology in a capitated managed care system: how do patients fare? Journal of Child and Adolescent Psychopharmacology 8(2):115–124, 1998PubMedCrossRef
Metadata
Title
Both Atomoxetine and Stimulants Improve Quality of Life in an ADHD Population Treated in a Community Clinic
Author
Leo Bastiaens
Publication date
01-06-2008
Publisher
Springer US
Published in
Psychiatric Quarterly / Issue 2/2008
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-008-9070-6

Other articles of this Issue 2/2008

Psychiatric Quarterly 2/2008 Go to the issue

Erratum

The Use of Data to Assist in the Design of a New Service System for Homeless Veterans in New York City

Original Paper

Reducing Inpatient Aggression: Does Paying Attention Pay Off?

Original Paper

Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice

Original Research

Professionals’ Attitudes Toward Reducing Restraint: The Case of Seclusion in The Netherlands

Original Paper

Examining Harry Thaw’s “Brain-Storm” Defense: APA and ANA Presidents as Expert Witnesses in a 1907 Trial

Original Paper

Efficacy of Couple Therapy as a Treatment for Depression: A Meta-Analysis